Literature DB >> 6328127

The basic mechanism of inotropic action of digitalis glycosides.

T W Smith.   

Abstract

A broad survey of the experimental literature suggests that the only unifying concept of digitalis action is that these drugs, at pharmacologically relevant doses, bind with high affinity and specificity to sites on the NaK-ATPase complex that face the outer surface of nearly all eukaryotic cells. Alternative receptors, if they exist, have not been defined. As might be expected, a broad range of biologic effects results from this basic interaction. The clinical therapeutic effects of digitalis include enhancement of myocardial contractility and changes in the properties of the cardiac conduction system; the latter, in turn, result from both direct and autonomically mediated effects [44]. Autonomic effects involve alterations in both parasympathetic and sympathetic activity, and these are attributable to both central and peripheral neural mechanisms [44]. As we have reviewed, there is compelling evidence that one mechanism leading to sustained positive inotropic effects of digitalis glycosides in heart muscle is partial inhibition of sodium transport. Earlier evidence [16, 17] is now supported by electrophysiologic studies [29, 30, 45, 46], intracellular ion-sensitive microelectrode methods [47, 48], and ion flux measurements using radioisotope tracers [14, 15, 49]. Inhibition of myocardial monovalent cation transport has been documented in intact glycoside-sensitive animal models at doses and plasma and myocardial levels causing a positive inotropic effect without overt toxicity [12]. However, these findings do not preclude other mechanisms that may be operative in addition to, or in some circumstances instead of, myocardial Na-K pump inhibition. In the context of much seemingly conflicting evidence [35, 36, 37, 50, 51], the hypothesis advanced by Akera and Brody is of interest [17]. These authors suggest that interaction of subtoxic digitalis concentrations with myocardial NaK-ATPase reduces maximum sodium transport capacity, resulting in an enhanced transient increase in [Na]i during the early phase of the cardiac cycle. Such an increase in subsarcolemmal [Na+] could cause increased Ca++ influx via Na+-Ca++ exchange, with a consequent positive inotropic effect. If the Na+ increase were cyclic and not cumulative, cell Na+ content could return to normal by the end of a cycle due to enhanced turnover of unblocked Na-K pump sites. This hypothesis suggests a mechanism by which Na-K pump inhibition could cause a positive inotropic effect without any measurable increase in steady-state [Na+]i or decrease in [K+]i.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328127

Source DB:  PubMed          Journal:  J Pharmacol        ISSN: 0021-793X


  10 in total

Review 1.  Transport ATPases in biological systems and relationship to human disease: a brief overview.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2002-10       Impact factor: 2.945

Review 2.  Endogenous ouabain: a link between sodium intake and hypertension.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 3.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

4.  The search of an ideal oral positive inotropic agent.

Authors:  L B Tan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Digoxin and cognitive performance in patients with heart failure: a cohort, pharmacoepidemiological survey.

Authors:  Alice Laudisio; Emanuele Marzetti; Francesco Pagano; Alberto Cocchi; Roberto Bernabei; Giuseppe Zuccalà
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole.

Authors:  J K Gwathmey; S E Warren; G M Briggs; L Copelas; M D Feldman; P J Phillips; M Callahan; F J Schoen; W Grossman; J P Morgan
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

7.  Comparison between ivabradine and low-dose digoxin in the therapy of diastolic heart failure with preserved left ventricular systolic function.

Authors:  Giuseppe Cocco; Paul Jerie
Journal:  Clin Pract       Date:  2013-11-04

Review 8.  On the Many Actions of Ouabain: Pro-Cystogenic Effects in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Jessica Venugopal; Gustavo Blanco
Journal:  Molecules       Date:  2017-05-03       Impact factor: 4.411

9.  Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor.

Authors:  Konstantinos Alevizopoulos; Konstantinos Dimas; Natalia Papadopoulou; Eva-Maria Schmidt; Anna Tsapara; Saad Alkahtani; Sabina Honisch; Kyriakos C Prousis; Saud Alarifi; Theodora Calogeropoulou; Florian Lang; Christos Stournaras
Journal:  Oncotarget       Date:  2016-04-26

10.  Enhanced genome editing in human iPSCs with CRISPR-CAS9 by co-targeting ATP1a1.

Authors:  Jui-Tung Liu; James L Corbett; James A Heslop; Stephen A Duncan
Journal:  PeerJ       Date:  2020-05-01       Impact factor: 2.984

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.